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 _____________________________________________________________________________________________________ 
This practical tool is now at the stage that it will be 
evaluated clinically in each centre. By now several centres 
have experience with image guided adaptive brachytherapy 
in limited numbers of patients with vaginal cancer. To gain 
more knowledge from this already existing experience a 
retrospective database has been established with inclusion of 
approximately 90 patients that have been treated with CT or 
MRI guided brachytherapy. Although different target concepts 
have been used, this cohort will allow for analysis of disease 
control, prognostic factors and descriptive analysis of the 
radiotherapy related parameters in a more contemporary 
series. A future goal will be establishment of a prospective 
multicentre database with inclusion of patients treated with 
a common target concept.  
During this presentation existing results for radiotherapy in 
vaginal cancer will be reviewed, followed by an overview of 
the work that has been performed to introduce image guided 
adaptive brachytherapy in primary vaginal cancer within the 
GEC ESTRO GYN group. 
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In this presentation the possibilities for image quantification 
for tissue characterization will be discussed that go beyond 
quantification of Hounsfield Units for CT or SUV for PET 
imaging. Standardization aspects of advanced imaging 
techniques are important for reliable and robust 
quantification. Besides the image acquisition, an equally 
important part is validation of the used image analysis 
techniques. Especially for textural feature calculations (e.g. 
radiomics) this is not a trivial task and may require some 
more detailed guidelines for acquisition, segmentation, 
analysis and reporting of results. The entire pipeline from 
image acquisition to analysis should be designed to allow 
interchangeable and robust results between e.g. institutes, 
software packages and imaging equipment. This presentation 
will illustrate the possibilities of advanced image 
quantification, concepts and techniques with clinical 
examples: Radiomics of tumours are currently investigated to 
predict local control, metastasis patterns or survival of 
patients, whereas advanced image quantification of normal 
tissues may allow better prediction of patients prone to 
toxicity. 
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Solid tumors may be heterogeneous with respect to 
radiosensitivity, and a homogeneous tumor dose is thus not 
always optimal. Thus, medical images of radiobiological 
relevance may be used to guide focal irradiation of tumors. 
Tumor control probability (TCP) modeling may be useful for 
optimizing dose painting treatment plans and for estimating 
the effect of such therapeutic strategies.  
Both magnetic resonance imaging and positron emission 
tomography may provide voxel-by-voxel maps potentially 
reflecting tumor aggressiveness and radioresistance. The talk 
will elaborate on the biological relevance of theses imaging 
approaches and their pros and cons in terms of radiotherapy 
planning. Then, from the voxelwise mapping of tumor 
radiosensitivity, proposed frameworks for the tumor control 
probability modelling will be presented. Both data-driven and 
model-driven approaches are discussed. Furthermore, the 
potential use of TCP modelling in dose painting will be 
elaborated. Also, the concept of ‘LET’ painting in particle 
therapy will be highlighted. 
In concluding, the current and future role of image based 
TCP modelling will be discussed, seen together with both 
advances in biologic imaging and in radiotherapy delivery and 
guidance techniques. 
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In this era, image-guided radiotherapy provides the 
technology to modulate dose based on the variation in 
radiation sensitivity within cancer of the prostate. This raises 
the question what to irradiate and to which dose. Here, 
functional imaging techniques play an essential role. Multi-
parametric (mp) MRI, consisting of T2-weighted, diffusion-
weighted and dynamic contrast-enhanced MRI is a key 
element in the detection of prostate cancer, and is 
increasingly used for delineation of tumors inside the 
prostate gland. Validation with histopathology however shows 
that tumor detection and particularly tumor delineation is 
challenging. Prostate cancer is often multifocal and small 
lesions (<0.5cm3) are often missed. Tumor sub-volumes with 
low cell and microvessel density that resemble healthy tissue 
are also difficult to find with mp-MRI.The most aggressive 
parts of the tumors, containing high cell and microvessel 
density and a higher Gleason score, are more likely to be 
detected. The heterogeneity in the histopathology of 
prostate cancer together with the limitations of mpMRI in 
detecting small satellites has implications for dose 
prescriptions in radiotherapy. We therefore evaluated the 
potential impact of dose differentiation on the tumor control 
probability (TCP) in prostate radiotherapy using 
histopathological properties of prostate tumors. We defined 
GTV and CTV based on tumor volumes on H&E stained slices 
from prostatectomy specimen of 25 patients. Each patients’ 
TCP was simulated taking into account differences in the cell 
numbers (N0) and Gleason Scores (GS). We further evaluated 
the assumption that these tumors all have the same 
radiosensitivity, or that radiosensitivity decreases with 
increasing Gleason grade. Our results demonstrate feasible 
dose differentiations between GTV and CTV based on the 
heterogeneity in the histopathology of prostate tumors and 
the impact on the TCP of the patient population. We will 
further discuss the different GTV-CTV dose differentiations 
considering heterogeneity only in the number of tumor cells 
or also in the radiosensitivity, based on Gleason grade. 
Further studies in carefully designed clinical trials are needed 
to determine the effect of heterogeneous radiosensitivity on 
the response of individual patients to different regimes of 
radiotherapy. 
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Purpose or Objective: Intrafraction motion is a challenge for 
accurate delivery of stereotactic body radiation therapy 
(SBRT) in the liver. Real-time treatment adaptation (gating, 
